- Home
- MGRX vs NCEL Comparison
MGRX vs NCEL Comparison
Compare MGRX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | NCEL |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 10.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGRX | NCEL |
|---|---|---|
| Price | $0.43 | $4.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 54.3K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $456,021.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $1.83 |
| 52 Week High | $2.75 | $4.99 |
Technical Indicators
Market Signals| Indicator | MGRX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 79.43 |
| Support Level | $0.32 | $2.50 |
| Resistance Level | $0.48 | $4.70 |
| Average True Range (ATR) | 0.05 | 0.33 |
| MACD | 0.01 | 0.28 |
| Stochastic Oscillator | 54.17 | 84.96 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.